- Home
- CBAN vs CRDF Comparison
CBAN vs CRDF Comparison
Compare CBAN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- CRDF
- Stock Information
- Founded
- CBAN 1975
- CRDF 1999
- Country
- CBAN United States
- CRDF United States
- Employees
- CBAN N/A
- CRDF N/A
- Industry
- CBAN Major Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBAN Finance
- CRDF Health Care
- Exchange
- CBAN Nasdaq
- CRDF Nasdaq
- Market Cap
- CBAN 295.6M
- CRDF 288.7M
- IPO Year
- CBAN 1998
- CRDF N/A
- Fundamental
- Price
- CBAN $16.34
- CRDF $3.74
- Analyst Decision
- CBAN
- CRDF Strong Buy
- Analyst Count
- CBAN 0
- CRDF 4
- Target Price
- CBAN N/A
- CRDF $12.00
- AVG Volume (30 Days)
- CBAN 82.1K
- CRDF 1.1M
- Earning Date
- CBAN 04-23-2025
- CRDF 05-01-2025
- Dividend Yield
- CBAN 2.81%
- CRDF N/A
- EPS Growth
- CBAN 9.88
- CRDF N/A
- EPS
- CBAN 1.36
- CRDF N/A
- Revenue
- CBAN $112,401,000.00
- CRDF $683,000.00
- Revenue This Year
- CBAN $14.25
- CRDF N/A
- Revenue Next Year
- CBAN $6.28
- CRDF N/A
- P/E Ratio
- CBAN $11.97
- CRDF N/A
- Revenue Growth
- CBAN 1.93
- CRDF 39.96
- 52 Week Low
- CBAN $10.33
- CRDF $2.01
- 52 Week High
- CBAN $18.49
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- CBAN 48.06
- CRDF 43.91
- Support Level
- CBAN $15.55
- CRDF $3.52
- Resistance Level
- CBAN $16.59
- CRDF $4.42
- Average True Range (ATR)
- CBAN 0.38
- CRDF 0.29
- MACD
- CBAN 0.02
- CRDF -0.04
- Stochastic Oscillator
- CBAN 66.67
- CRDF 18.89
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division, and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").